ArticleIranian journal of biotechnology2025
Identification and Validation of Tumorigenesis Related Hub Genes in Hepatocellular Carcinoma via Integrated Bioinformatics Analysis.
Article in Iranian journal of biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) is a heterogeneous liver cancer with poor prognosis and diverse etiologies, yet molecular mechanisms across different causes remain unclear. Objective: To identify key gene expression patterns and pathways associated with HCC progression from diverse pathological backgrounds using integrated bioinformatics analysis. Materials and Methods: Seven HCC-related GEO datasets totaling 1219 samples were analyzed. Differentially expressed genes (DEGs) were identified, followed by pathway enrichment, survival analysis, and immunohisto-chemistry validation. Results: We identified DEGs such as CBS, ELF3, SPP2, and RPL8 correlated with patient survival. Enrichment analysis highlighted the PI3K-Akt signaling pathway as a central route in liver cirrhosis and tumor progression. A 47-gene set was proposed as a potential regulatory 'brake' during benign-to-malignant transformation. These findings were consistent with recent studies emphasizing PI3K-Akt and metabolic dysregulation in HCC pathogenesis. Conclusions: Our integrative analysis reveals critical genes and pathways involved in HCC development, providing potential prognostic biomarkers and therapeutic targets. The study underscores the importance of cirrhosis in HCC progression and highlights the PI3K-Akt pathway's pivotal role. Further functional validation and larger cohort studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.